Huntington disease

Last updated: August 15, 2022

Summarytoggle arrow icon

Huntington disease (HD) is a neurodegenerative movement disorder characterized by involuntary and irregular movements of the limbs, neck, head, and/or face (chorea). This autosomal-dominant inherited disease is caused by mutations (increased number of CAG trinucleotide repeats) in the huntingtin gene which eventually leads to the dysfunction of subcortical motor circuits. Symptom onset depends on the individual extent of the genetic abnormalities but usually occurs around 40 years of age. In later stages, psychiatric symptoms like dementia and depression are common. To date, no disease-modifying treatment is available. Management involves symptomatic treatment and supportive care. On average, HD leads to death within 15–20 years after symptom onset.

  • Sex: =
  • Peak incidence [1]
    • 40 years of age (symptom onset usually between 20 and 50 years of age)
    • One of the most common hereditary diseases of the brain
  • Peak prevalence: 3–7 per 100,000 people of Western European descent (compared to 1 per 100,000 people of Asian and African descent) [2]

Epidemiological data refers to the US, unless otherwise specified.

  • Increased number of CAG repeats (trinucleotide or triplet repeat expansion) in the huntingtin gene on chromosome 4 (most likely due to DNA polymerase dysfunction) results in the expression of an altered huntingtin protein.
    • Huntingtin is physiologically expressed throughout the CNS, but its exact function is not known.
    • 40 or more CAG repeats result in almost certain development of HD .
  • Inheritance [3]
    • Autosomal dominant
    • Anticipation: increase in the number of CAG repeats in subsequent generations
    • Imprinting: Paternal inheritance causes more CAG triplets.


Molecular and cellular changes lead to neuronal loss and gliosis in the striatum (particularly in the caudate nucleus) and, subsequently, the thalamus and the cortex.


  • Overall levels of abnormal huntingtin protein correlate with the severity of symptoms.
  • The striatum normally controls movement via inhibitory outputs to the globus pallidus internus (direct pathway) and globus pallidus externus (indirect pathway). [4]
    • Direct pathway
      • Striatal projections inhibit the internal globus pallidus, which normally inhibits the thalamus and its excitatory projections to the cortex.
      • Activation of the direct pathway generally results in increased transmission to the cortex.
    • Indirect pathway
  • In HD, the indirect pathway is commonly affected earlier than the direct pathway. [3]
    • Early stages: only the indirect pathway is affected → increased dopaminergic transmission excess cortical activity → hyperkinetic/choreatic movements [5]
    • Later stages: both pathways are affected: , which, together with additional factors → overall decrease of excitatory thalamic transmission to the cortex → hypokinetic/akinetic symptoms
  • Neuronal injury and death is caused by overactivation of N-methyl-D-aspartate (NMDA) receptors through excessive glutamate stimulation (glutamate-induced excitotoxicity), which leads to:
    • Alteration of GABAergic neurotransmission → decreased GABA in the brain
    • Dysfunction of cholinergic transmission (early stage) and loss of cholinergic neurons (late stage) → decreased acetylcholine (Ach) in the brain [6]

In Huntington disease, increased number of CAG repeats leads to the damage to the Caudate nucleus and results in decreased Ach and GABA.

Chorea characterizes the early stages of the disease while hypokinetic/akinetic symptoms may dominate later on. Dementia, depression, and behavioral disorders are common in advanced stages.

Chorea and/or athetosis may occur in all of the presented diseases. Only common distinguishing signs and symptoms are listed below.

Differential diagnosis of choreoathetoid movement disorders

Epidemiology & etiology Signs & symptoms Diagnostics

Huntington disease [7]

Sydenham chorea [11]

  • Motor symptoms
  • Neuropsychiatric symptoms (e.g., inappropriate laughing/crying, obsessive-compulsive behavior)
  • Atypical symptoms (e.g., fever, fatigue, malaise)

Wilson disease [12]

  • Usually younger or middle-aged men or women
  • Genetic (mutations in hepatic copper transport protein ATP7B)

Creutzfeldt-Jakob disease [13]

  • Very rare
  • Infectious (prion particles)
  • Rapid progression

Systemic lupus erythematosus (SLE) [14][15]

  • Most commonly affects women of childbearing age
  • Chronic inflammatory, possibly autoimmune (exact cause unknown)
Ballismus [17]

Drug-induced chorea [17][19]

  • Twisting movements of the tongue and of the fingers
  • Lip smacking, chewing movements
  • Ballistic limb movements, foot tapping
  • Postural abnormalities
  • Laboratory (toxicology screen)

The differential diagnoses listed here are not exhaustive.

General approach

  • Ongoing physiotherapeutic, ergotherapeutic, and logotherapeutic care
  • Psychotherapy (if needed)
  • Consultation of specially trained counselors (if genetic diagnostics are employed)

Medical therapy [20]

There is no causal therapy available.

  1. Holtz JL. Applied Clinical Neuropsychology: An Introduction. Springer Publishing Company ; 2010
  2. Huntington disease. Updated: August 17, 2020. Accessed: September 9, 2020.
  3. Zoghbi HY, Orr HT. Huntington disease: Genetics and pathogenesis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: March 28, 2016. Accessed: March 30, 2017.
  4. Kasper DL, Fauci AS, Hauser SL, Longo DL, Lameson JL, Loscalzo J. Harrison's Principles of Internal Medicine. McGraw-Hill Education ; 2015
  5. Carlos Cepeda, Kerry P.S. Murphy, Martin Parent, Michael S. Levine. The role of dopamine in huntington's disease. Elsevier ; 2014 : p. 235-254
  6. Gary X. D’Souza, Henry J. Waldvogel. Targeting the Cholinergic System to Develop a Novel Therapy for Huntington’s Disease. Journal of Huntington's Disease. 2016; 5 (4): p.333-342. doi: 10.3233/JHD-160200 . | Open in Read by QxMD
  7. Suchowersky O. Huntington disease: Clinical features and diagnosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: October 19, 2016. Accessed: March 30, 2017.
  8. Perez-Perez J, Diaz-Manera J, Pagonabarraga J et al. Hung up knee jerk reflex in Huntington's disease: A clinical and neurophysiological study . Mov Disord. 2017; 32 .
  9. Schiffer RB, Rao SM, Fogel BS. Neuropsychiatry. Lippincott Williams & Wilkins ; 2003
  10. Natalia P. Rocha, Benson Mwangi, Carlos A. Gutierrez Candano, Cristina Sampaio, Erin Furr Stimming, Antonio L. Teixeira. The Clinical Picture of Psychosis in Manifest Huntington's Disease: A Comprehensive Analysis of the Enroll-HD Database. Frontiers in Neurology. 2018; 9 . doi: 10.3389/fneur.2018.00930 . | Open in Read by QxMD
  11. Gilbert DL. Sydenham chorea. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: September 2, 2016. Accessed: February 13, 2017.
  12. Schilsky ML. Wilson disease: Clinical manifestations, diagnosis, and natural history. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: November 10, 2015. Accessed: January 6, 2017.
  13. Brown HG, Lee JM. Creutzfeldt-Jakob disease. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: August 9, 2013. Accessed: March 30, 2017.
  14. Schur PH, Hahn BH, Pisetsky DS, Ramirez Curtis M. Epidemiology and pathogenesis of systemic lupus erythematosus. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: April 26, 2017. Accessed: July 7, 2017.
  15. Wallace DJ. Diagnosis and Differential Diagnosis of Systemic Lupus Erythematosus in Adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: November 23, 2015. Accessed: March 30, 2017.
  16. Schur PH. Neurologic manifestations of systemic lupus erythematosus. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: February 24, 2017. Accessed: March 30, 2017.
  17. Suchowersky O. Overview of chorea. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: June 22, 2020. Accessed: September 9, 2020.
  18. Defebvre L, Krystkowiak P. Movement disorders and stroke. Rev Neurol (Paris). 2016; 172 (8-9): p.483-487. doi: 10.1016/j.neurol.2016.07.006 . | Open in Read by QxMD
  19. Deik A, Tarsy D. Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: July 30, 2020. Accessed: September 10, 2020.
  20. Suchowersky O. Huntington disease: Management. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: October 27, 2016. Accessed: March 30, 2017.
  21. Dean M, Sung V. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug Design, Development and Therapy. 2018; Volume 12 : p.313-319. doi: 10.2147/dddt.s138828 . | Open in Read by QxMD
  22. Jones U, Busse M, Enright S, Rosser AE. Respiratory Decline is Integral to Disease Progression in Huntington's Disease. European Respiratory Journal. 2016; 50 (1). doi: 10.1183/13993003.02215-2015 . | Open in Read by QxMD
  23. Gladman DD. Overview of the Clinical Manifestations of Systemic Lupus Erythematosus in Adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. updated: September 10, 2015. Accessed: March 30, 2017.

3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer